Drug-targeting strategies in cancer therapy

被引：63

作者：

Huang, PS ^{[1
]}

Oliff, A ^{[1
]}

机构：

[1] Dupont Pharmaceut Co, Dept Canc Res, Glenolden, PA 19036 USA

来源：

CURRENT OPINION IN GENETICS & DEVELOPMENT | 2001年 / 11卷 / 01期

关键词：

D O I：

10.1016/S0959-437X(00)00164-7

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Genetic changes in cell-cycle, apoptotic, and survival pathways cause tumorigenesis, leading to significant phenotypic changes in transformed cells. These changes in the tumor environment - elevated expression of surface proteases, increased angiogenesis and glucuronidase activity - can be taken advantage of to improve the therapeutic index of exisiting cancer therapies. Targeting cytotoxics to tumor cells by enzymatic activation is a promising strategy for improving chemotherapeutics.

引用

页码：104 / 110

页数：7

共 50 条

[1]

Ahmad I, 1999, ONCOL RES, V11, P273

[2] Doxorubicin represses CARP gene transcription through the generation of oxidative stress in neonatal rat cardiac myocytes: Possible role of serine/threonine kinase-dependent pathways [J].

Aihara, Y ;

Kurabayashi, M ;

Tanaka, T ;

Takeda, S ;

Tomaru, K ;

Sekiguchi, K ;

Ohyama, Y ;

Nagai, R .

JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2000, 32 (08) :1401-1414

[3] Intensely cytotoxic anthracycline prodrugs: Glucuronides [J].

Bakina, E ;

Wu, Z ;

Rosenblum, M ;

Farquhar, D .

JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (25) :4013-4018

[4] Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238 [J].

Benali, N ;

Cordelier, P ;

Calise, D ;

Pagès, P ;

Rochaix, P ;

Nagy, A ;

Estève, JP ;

Pour, PM ;

Schally, AV ;

Vaysse, N ;

Susini, C ;

Buscail, L .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (16) :9180-9185

[5]

Bosslet K, 1998, CANCER RES, V58, P1195

[6] The antitumour activity of the prodrug N-L-leucyl-doxorubicin and its parent compound doxorubicin in human tumour xenografts [J].

Breistol, K ;

Hendriks, HR ;

Berger, DP ;

Langdon, SP ;

Fiebig, HH ;

Fodstad, O .

EUROPEAN JOURNAL OF CANCER, 1998, 34 (10) :1602-1606

[7] Superior therapeutic efficacy of N-L-leucyl-doxorubicin versus doxorubicin in human melanoma xenografts correlates with higher tumour concentrations of free drug [J].

Breistol, K ;

Hendriks, HR ;

Fodstad, O .

EUROPEAN JOURNAL OF CANCER, 1999, 35 (07) :1143-1149

[8] Synthesis and biological evaluation of 2′-carbamate-linked and 2′-carbonate-linked prodrugs of paclitaxel:: Selective activation by the tumor-associated protease plasmin [J].

de Groot, FMH ;

van Berkom, LWA ;

Scheeren, HW .

JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (16) :3093-3102

[9] Synthesis and biological evaluation of novel prodrugs of anthracyclines for selective activation by the tumor-associated protease plasmin [J].

de Groot, FMH ;

de Bart, ACW ;

Verheijen, JH ;

Scheeren, HW .

JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (25) :5277-5283

[10] A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo [J].

DeFeo-Jones, D ;

Garsky, VM ;

Wong, BK ;

Feng, DM ;

Bolyar, T ;

Haskell, K ;

Kiefer, DM ;

Leander, K ;

McAvoy, E ;

Lumma, P ;

Wai, J ;

Senderak, ET ;

Motzel, SL ;

Keenan, K ;

Van Zwieten, M ;

Lin, JH ;

Freidinger, R ;

Huff, J ;

Oliff, A ;

Jones, RE .

NATURE MEDICINE, 2000, 6 (11) :1248-1252

← 1 2 3 4 5 →